BDBM439423 US10633345, Compound 107f::US11203574, Compound 107f::US11230530, Compound 107f::US11708332, Compound 107f

SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccc(OCc2ccccc2)c1)C(F)(F)F

InChI Key InChIKey=VWRITWGTGWRWCP-UHFFFAOYSA-N

Data  5 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 439423   

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439423(US10633345, Compound 107f | US11230530, Compound 1...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439423(US10633345, Compound 107f | US11230530, Compound 1...)
Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439423(US10633345, Compound 107f | US11230530, Compound 1...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439423(US10633345, Compound 107f | US11230530, Compound 1...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/17/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439423(US10633345, Compound 107f | US11230530, Compound 1...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2023
Entry Details
US Patent